Description: All you wanted to know about InsurTech but were too afraid to ask! This one-day event will feature four webcasts that will unlock and enhance the world of InsurTech. By attending this webs series, you will find answers on what InsurTech is about and what it’s trying to solve. Dive deeper into the successes of InsurTech and find out how to join this established organization. Session 1 – Introduction to InsurTech Set the stage for the day, defining the main types of InsurTech companies and where these companies fit in the insurance value chain. Come discover where actuaries could play a role and the importance of the profession within this space. Technology driven innovation is multifaceted and could take place within an established carrier or a start-up.

Description: Creating an effective team is core to actuarial transformation. This involves establishing teams with jobs that line up to achieve the company's goals, with clear roles that engage people and enable them to develop. Coupled with this, effective teams need to harness the benefits of diversity. This is done both directly and through sponsorship and allyship to ensure that the full benefit of diverse teams can be realized with multiple viewpoints and perspectives strengthening teams. During the sessions, the speakers will draw on their experiences from around the world on, building global and diverse teams. By attending this session, you will:•Be able to gain insight on the benefits of embracing diversity when creating an actuarial team across the globe, and how sponsorship and allyship in workplace foster an inclusive environment.

Description: With the ever changing economic and regulatory environment along with emerging experience, companies face real challenges managing non-guaranteed elements (NGE) for life and annuity business. Explore the opportunities and challenges offered by NGE management, with consideration for market trends, regulations, and the new ASOP 2. By attending the session, you will: - Understand recent market trends in NGE management for life and annuities. - Better appreciate the regulatory and compliance requirements surrounding NGEs especially the revised ASOP 2. - Understand the risks of action and inaction on NGEs.

Description: The old adage 'insurance is sold not bought' has been used to dismiss digital insurance and support the old agent model of distribution. However, modern distribution systems address this with personalization. This is not simply a customized application form based on age or gender. Personalization is much more dynamic and happens in real-time. It's about tailoring the end-to-end experience to meet the needs and expectations of the specific applicant. The core tools to achieve this are AI learning and nudges from behavioral science.

Description: Do you know how you would handle yourself in a high visibility situation that put your professionalism in the spotlight? How would you handle being reported to the ABCD? Hear how, Tom Dlouhy, after taking a new assignment, quickly found himself challenged from many angles but came out a stronger actuary. This lunch session is a reprise of a presentation from the 2017 Seattle Life and Annuity Symposium with some new highlights. Hear Tom share his experience with the ASOPs, the ABCD, and how he attempted to maintain the high standards of actuarial professionalism.

Description: The actuarial profession is changing rapidly and the skills needed to be successful are also changing. In this session, we will debate key topics and questions, such as: What is the predominant future career path for actuaries? Specialists or generalists? Does the actuarial profession have a meaningful value prop outside our core domains e.g. insurance? What skills are needed for the actuary of the future? What’s the best approach to improve actuarial storytelling to non-actuarial audiences? What’s the role of actuaries to managing and predicting emerging trends and assumptions? What is the role of actuaries in relation to development and ownership of advanced modeling? Is the future actuarial profession smaller/larger than it is today? In either case, how does it differ from today in terms of make-up, deployment, function, purpose, value add, etc.?

Description: In this video Mitchell Momanyi, FSA MAAA presents an informative breakdown of Medicare Advantage plans, delving into the intricacies of this alternative to traditional Medicare. Covering the inception of Medicare Advantage and its evolution, Momanyi explores the managed care companies offering Part C coverage, emphasizing the role of provider networks coordinated care. Concluding with key considerations for beneficiaries, Momanyi stresses the importance of weighing the pros and cons between Traditional Medicare and Medicare Advantage, while also emphasizing the evolving nature of the Medicare landscape and the regulatory nuances influencing enrollment decisions. Conributors: Mitchell Momanyi, FSA, MAAA, Deana Bell FSA, MAAA, Matt Emery, FSA, CERA, MAAA, Jon Forster, ASA, MAAA

Description: Creating a predictive model is one thing, but then taking that model and getting full stakeholder buy-in is another. Learn from presenters' experiences and insights on proving model effectiveness in the long-term care (LTC), life and annuity spaces. Explore various topics such as feasibility, model transparency, fairness and equity, ROI measurement, data assets and compliance, infrastructure and more. By the end of the session, you will gain an understanding of how to navigate the challenges of proving the effectiveness of predictive modeling and obtaining management buy-in.

Description: Cover a variety of topics centered around the unsupervised learning technique called 'clustering'. The presenters will take you through a wide array of topics that range from 'What is Clustering?' to 'How can I use this technique to solve problems I didn't even know existed?' In the health care industry, everyone is looking for an edge in reducing total spend-cluster analysis finds the unambiguous in an ambiguous framework of results.

Description: Hear about the new hope biosimilars bring in helping payers and patients manage the rapidly growing pharmacy spend. The Big Event, encompassing multiple Humira biosimilars, launches in 2023 and could set the tone for how much biosimilars can be expected to contribute to solving our pharmacy spend challenges. What will be the financial impact of the Big Event and this coming wave? What can be done to maximize adoption of biosimilars? What strategies are available to maximize savings for payers and patients?